SCHEMBL3633228

SCHEMBL3633228

COC(=O)c1ccc(NC(=O)CCC(=O)O)cc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.64
ALDH1A1 P00352 3/20 0.59
KDM4E B2RXH2 2/20 0.59
HPGD P15428 2/20 0.59
HSD17B10 Q99714 2/20 0.59
CYP1A1 P04798 1/20 0.54
KMT2A Q03164 1/20 0.52
CA12 O43570 2/20 0.51
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
CA9 Q16790 2/20 0.51
CA14 Q9ULX7 2/20 0.51
CA7 P43166 1/20 0.51
PDK2 Q15119 1/20 0.51
PDK4 Q16654 1/20 0.51
POLB P06746 2/20 0.51
CYP1A2 P05177 1/20 0.51
EGFR P00533 1/20 0.50
TSHR P16473 1/20 0.50
EPHX2 P34913 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL3629891 0.88 GAA (0.58) SMN1; SMN2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2129381 0.87 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL23906981 0.84 ALDH1A1 (0.58) SMN1; SMN2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5497587 0.82 CYP1A1 (0.57) ALDH1A1KDM4ECYP1A1KMT2ACA12
SCHEMBL7858895 0.80 PTPRC (0.58) SMN1; SMN2ALDH1A1KDM4EHPGDKMT2A
SCHEMBL13593266 0.80 KMT2A (0.61) ALDH1A1KDM4ECYP1A1KMT2ACA12
SCHEMBL11892329 0.80 EGFR (0.56) SMN1; SMN2HSD17B10KMT2ACA12CA1
SCHEMBL23309774 0.79 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1KDM4EHPGDKMT2A
SCHEMBL2127575 0.79 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL613429 0.79 SMN1; SMN2 (0.76) SMN1; SMN2KDM4EHPGDHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9149530-B2 Compositions and methods for enhancing active agent absorption NEXUS PHARMA, INC. (US) 2015-10-06 US disclosed
US-8426466-B2 Compositions and methods for enhancing active agent absorption NEXUS PHARMA, INC. (US) 2013-04-23 US disclosed
EP-2150243-A2 COMPOSITIONS AND METHODS FOR ENHANCING ACTIVE AGENT ABSORPTION Nexus Pharma, Inc. (US) 2010-02-10 EP disclosed
WO-2008144690-A2 COMPOSITIONS AND METHODS FOR ENHANCING ACTIVE AGENT ABSORPTION NEXUS PHARMA, INC. (US) 2008-11-27 WO disclosed
US-20070269500-A1 Compositions and methods for enhancing active agent absorption NEXUS PHARMA, INC. 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070269500-A1 Compositions and methods for enhancing active agent absorption FABP2, SLC10A2, SI SMN1; SMN2 1589/4885ALDH1A1 1881/4885KDM4E 4357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.